

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*Unless otherwise defined herein, capitalised terms in this announcement shall have the same meanings as those defined in the prospectus dated 15 December 2022 (the “**Prospectus**”) issued by Guanze Medical Information Industry (Holding) Co., Ltd. (the “**Company**”).*

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any Shares or other securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares thereby being offered. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

*This announcement is not for release, publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a part of any offer to sell or a solicitation of an offer to buy securities in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”), or any applicable state securities laws, and may not be offered, sold, pledged or transferred in the United States unless pursuant to an exemption from, or in a transaction that is not subject to, the registration requirements of the U.S. Securities Act and any applicable state securities laws. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act. There will be no public offering of the securities of the Company in the United States.*

The Overall Coordinator and Joint Global Coordinators confirm that there has been no over-allocation of the Offer Shares under the International Offering and the Over-allotment Option will not be exercised. In view of the fact that there has been no over-allocation of the Offer Shares under the International Offering, no stabilisation activity as described in the Prospectus will take place during the stabilisation period.

Potential investors of the Offer Shares should note that the Overall Coordinator and the Joint Global Coordinators (for themselves and on behalf of the Hong Kong Underwriters and the Capital Market Intermediaries) shall be entitled to terminate its obligations under the Hong Kong Underwriting Agreement upon occurrence of any of the events set out in the section headed “Underwriting — Underwriting Arrangements and Expenses — The Hong Kong Public Offering — Hong Kong Underwriting Agreement — Grounds for termination” in the Prospectus at any time prior to 8:00 a.m. on the Listing Date (Hong Kong time) (which is currently expected to be on Thursday, 29 December 2022).

Guanze Medical Information Industry (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

GLOBAL OFFERING

Number of Offer Shares under : 192,850,000 Shares
the Global Offering
Number of Hong Kong Offer Shares : 19,285,000 Shares
Number of International Offer Shares : 173,565,000 Shares
Offer Price : HK\$0.53 per Offer Share, plus brokerage
of 1%, SFC transaction levy of
0.0027%, AFRC transaction levy of
0.00015% and Stock Exchange trading
fee of 0.005% (payable in full on
application in Hong Kong dollars and
subject to refund)
Nominal value : HK\$0.01 per Share
Stock code : 2427

Sole Sponsor



Overall Coordinator



Joint Global Coordinators



Joint Bookrunners and Joint Lead Managers

